EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieOpen Access

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826

Sharon M Castellino iD, Hongli Li iD, Alex F Herrera iD, Michael LeBlanc, Susan K Parsons iD, Joseph M Unger iD, Angela Punnett, David Hodgson iD, Frank G Keller iD, Richard A Drachtman, Adam Lamble iD, Christopher J Forlenza und 10 weitere

Journal of Clinical Oncology · 20.02.2026 · 44 (6) · 449-454

DOI: 10.1200/jco-25-00203 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2026. Verfasst von Sharon M Castellino und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine, Atlanta, GA. Hauptthemen laut MEDLINE: Hodgkin Disease, Brentuximab Vedotin, Antineoplastic Combined Chemotherapy Protocols, Nivolumab. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseBrentuximab VedotinAntineoplastic Combined Chemotherapy ProtocolsNivolumabHumansAdolescentFemaleMaleChildDacarbazineDoxorubicinVinblastineFollow-Up StudiesNeoplasm StagingProgression-Free Survival

Substanzen

Brentuximab VedotinDacarbazineDoxorubicinNivolumabVinblastine

Autor:innen und Institutionen

  • Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.
  • SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.
  • City of Hope, Duarte, CA.
  • Division of Hematology/Oncology, Tufts Medical Center, Institute for Clinical Research and Health Policy Studies, Boston, MA.
  • The Hospital for Sick Children, Toronto, Canada.

ORCID-Profile: Sharon M Castellino, Hongli Li, Alex F Herrera, Susan K Parsons, Joseph M Unger, David Hodgson, Frank G Keller, Adam Lamble, Andrew Doan, Sarah C Rutherford, Andrew M Evens, Richard F Little, Malcolm A Smith, Bradford S Hoppe, Joo Y Song, Kara M Kelly

Förderung

  • NCI NIH HHS

Zitieren

APA

Castellino, S. M., Li, H., Herrera, A. F., LeBlanc, M., Parsons, S. K., Unger, J. M., Punnett, A., Hodgson, D., Keller, F. G., Drachtman, R. A., Lamble, A., Forlenza, C. J., Doan, A., Rutherford, S. C., Evens, A. M., Little, R. F., Smith, M. A., Hoppe, B. S., Song, J. Y., …, & Kelly, K. M. (2026). Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. Journal of Clinical Oncology, 44(6), 449-454. https://doi.org/10.1200/jco-25-00203

Vancouver

Castellino SM, Li H, Herrera AF, LeBlanc M, Parsons SK, Unger JM, et al. Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. Journal of Clinical Oncology. 2026;44(6):449-454. doi:10.1200/jco-25-00203

BibTeX
@article{Castellino2026,
  author = {Castellino, Sharon M and Li, Hongli and Herrera, Alex F and LeBlanc, Michael and Parsons, Susan K and Unger, Joseph M and Punnett, Angela and Hodgson, David and Keller, Frank G and Drachtman, Richard A and Lamble, Adam and Forlenza, Christopher J and Doan, Andrew and Rutherford, Sarah C and Evens, Andrew M and Little, Richard F and Smith, Malcolm A and Hoppe, Bradford S and Song, Joo Y and Smith, Sonali M and Friedberg, Jonathan W and Kelly, Kara M},
  title = {Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {6},
  pages = {449--454},
  doi = {10.1200/jco-25-00203}
}
Kostenlos starten →